Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.Filo + MVA-BN-Filo
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad26.Filo + MVA-BN-Filo is a heterologous prime-boost vaccine regimen developed by Janssen Vaccines in collaboration with Bavarian Nordic to provide broad protection against major filoviruses. The regimen consists of a priming dose, Ad26.Filo, which is a mixture of three recombinant adenovirus serotype 26 (Ad26) vectors, each expressing the glycoprotein (GP) of either Ebola virus (Zaire), Sudan virus, or Marburg virus. This is followed approximately 8 weeks later by a booster dose of MVA-BN-Filo (marketed as Mvabea), a recombinant, non-replicating Modified Vaccinia Ankara (MVA) vector. The MVA component encodes the glycoproteins of Ebola, Sudan, and Marburg viruses, as well as the nucleoprotein of the Taï Forest virus. This strategy is designed to elicit robust and durable humoral and cellular immune responses across multiple filovirus species. The regimen has been evaluated in Phase 1, 2, and 3 clinical trials and has demonstrated favorable safety and immunogenicity profiles in both adults and children.
- Other names
- Janssen Filovirus VaccineTrivalent Filovirus VaccineAd26.Filo/MVA-BN-Filo
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on Ad26.Filo + MVA-BN-Filo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.Filo + MVA-BN-Filo.